As the global burden of autoimmune diseases continues to escalate, Hashimoto thyroiditis has emerged as a critical therapeutic area demanding innovative solutions and strategic market approaches. This progressive autoimmune condition, affecting the thyroid gland’s ability to produce essential hormones, presents both significant clinical challenges and substantial commercial opportunities for the pharmaceutical industry. Current Market Landscape Read.